Founded in 1946, the company changed to its current name in the 1980's as it began to focus on the production of pharmaceuticals. SCHWARZ PHARMA develops and markets innovative drugs with the focus on Central Nervous System (CNS) as well as cardiovascular and gastro-intestinal diseases. The company is committed to provide excellent services to their customers and creating significant value for their investors. It strives to serve unmet medical needs by developing and marketing innovative products for specialty markets. SCHWARZ PHARMA AG is a member of UCB group, Brussels, Belgium.